市場調査レポート

商品コード

1707950

がんバイオマーカーの市場規模、シェア、成長分析、プロファイリング技術別、がんの種類別、製品別、用途別、エンドユーザー別、地域別 - 産業予測 2025～2032年

Cancer Biomarkers Market Size, Share, and Growth Analysis, By Profiling Technology (Omics Technology, Imaging Technologies), By Cancer Type (Breast Cancer, Lung Cancer), By Product, By Application, By End User, By Region - Industry Forecast 2025-2032

出版日: 2025年04月09日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 774,224円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 905,696円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,037,168円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.08円

全表示
概要
目次

概要

サンプル依頼リストに入れる

がんバイオマーカー市場規模は2023年に271億米ドルと評価され、2024年の304億9,000万米ドルから2032年には782億2,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは12.5%で成長する見通しです。

世界のがんバイオマーカー市場は、世界のがん罹患率の増加と腫瘍学研究への投資の高まりに牽引され、大きく成長する見通しです。診断精度と治療効果の向上におけるがんバイオマーカーの重要な役割に対する認識の高まりは、この分野の企業に新たな道を開くと期待されています。さらに、個別化医療や遺伝子治療の動向の高まりは、がんバイオマーカーの利用をさらに促進すると予想されます。技術の進歩は、非侵襲的で低侵襲な方法への嗜好と相まって、さらなる機会を生み出すと思われます。しかし、臨床的妥当性に対する懸念、ヘルスケア専門家の限られた認識、倫理的問題、厳しい規制状況などの課題は、今後数年間の市場の進展を制約する可能性があります。

市場概要
オミックス技術
- プロテオミクス
- 免疫測定
- 質量分析
- 2Dゲル電気泳動
- タンパク質マイクロアレイ
- その他
- ゲノミクス
- 次世代シーケンシング
- ポリメラーゼ連鎖反応
- インサイチューハイブリダイゼーション
- その他
画像テクノロジー
- 超音波画像診断
- コンピュータ断層撮影
- 磁気共鳴画像法
- 陽電子放出断層撮影
- マンモグラフィー

がんバイオマーカー市場規模：がんの種類別& CAGR（2025-2032）

市場概要
乳がん
肺がん
大腸がん
前立腺がん
黒色腫
白血病
甲状腺がん
膀胱がん
非ホジキンリンパ腫
腎臓がん
その他

がんバイオマーカー市場規模：製品別& CAGR（2025-2032）

市場概要
機器
- 画像機器
- 病理学に基づく機器
- 生検器具
消耗品
- 抗体
- キットと試薬
- プローブ
バイオインフォマティクス・ソフトウェア

がんバイオマーカー市場規模：用途別& CAGR（2025-2032）

市場概要
診断
研究開発
予後
リスクアセスメント
その他の用途

がんバイオマーカー市場規模：エンドユーザー別& CAGR（2025-2032）

市場概要
診断検査室
バイオ医薬品企業とクロス
調査・学術機関
その他

がんバイオマーカー市場規模：地域別& CAGR（2025-2032）

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022-2024年）

主要企業プロファイル

F. Hoffmann-La Roche AG（Switzerland）
Thermo Fisher Scientific Inc.（USA）
QIAGEN N.V.（Germany/Netherlands）
Agilent Technologies, Inc.（USA）
Abbott Laboratories（USA）
Illumina, Inc.（USA）
Bio-Rad Laboratories, Inc.（USA）
Myriad Genetics, Inc.（USA）
Guardant Health, Inc.（USA）
Exact Sciences Corporation（USA）
Sysmex Corporation（Japan）
Danaher Corporation（USA）
PerkinElmer, Inc.（USA）
DiaSorin S.p.A.（Italy）
BioMerieux SA（France）
Natera, Inc.（USA）
Adaptive Biotechnologies Corporation（USA）
NeoGenomics, Inc.（USA）

結論と提言

Product Code: SQMIG35A2775

Cancer Biomarkers Market size was valued at USD 27.1 billion in 2023 and is poised to grow from USD 30.49 billion in 2024 to USD 78.22 billion by 2032, growing at a CAGR of 12.5% during the forecast period (2025-2032).

The global cancer biomarker market is poised for significant growth, driven by an increasing incidence of cancer worldwide and heightened investments in oncology research. Growing awareness of the critical role of cancer biomarkers in enhancing diagnostic accuracy and treatment efficacy is expected to open new avenues for companies in this sector. Additionally, the rising trend of personalized medicine and gene therapies is anticipated to further propel the utilization of cancer biomarkers. Technological advancements coupled with a preference for non-invasive and minimally invasive methods will create further opportunities. However, challenges such as concerns over clinical validity, limited awareness among healthcare professionals, ethical issues, and stringent regulatory landscapes could constrain market progress in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cancer Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cancer Biomarkers Market Segments Analysis

Global Cancer Biomarkers Market is segmented by Profiling Technology, Cancer Type, Product, Application, End User and region. Based on Profiling Technology, the market is segmented into Omics Technology and Imaging Technologies. Based on Cancer Type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Thyroid Cancer, Bladder Cancer, Non-Hodgkins Lymphoma, Kidney Cancer and Others. Based on Product, the market is segmented into Instruments, Consumables and Bioinformatics Software. Based on Application, the market is segmented into Diagnostics, Research and Development, Prognostics, Risk Assessment and Other Applications. Based on End User, the market is segmented into Diagnostic Laboratories, Biopharmaceutical Companies and Cros, Research and Academic Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cancer Biomarkers Market

The rising prevalence of cancer is largely attributed to poor lifestyle choices and the widespread adoption of unhealthy habits, leading to a significant increase in the number of individuals diagnosed with the disease. This alarming trend is a primary driver for the cancer biomarkers market, as these biomarkers are essential for both cancer diagnosis and treatment. Their critical function in identifying cancer early and facilitating targeted therapies has amplified the demand for cancer biomarkers globally, reflecting the urgent need for effective diagnostic tools and treatment options in the growing battle against cancer.

Restraints in the Cancer Biomarkers Market

The Cancer Biomarkers market faces significant challenges, primarily due to concerns surrounding the privacy and ethical use of the molecular and genetic data from patients. Since cancer biomarkers provide insights that go beyond mere identification, they carry sensitive information about an individual's health. As public awareness and apprehension regarding data privacy rise, it is likely to inhibit the growth and demand for cancer biomarkers in the near future. Companies operating in this sector must navigate these issues carefully to maintain trust and foster adoption while ensuring compliance with evolving regulations related to personal health information.

Market Trends of the Cancer Biomarkers Market

The Cancer Biomarkers market is witnessing a significant trend towards the integration of artificial intelligence (AI) and machine learning technologies, revolutionizing biomarker research and diagnostics. Companies are leveraging AI to analyze extensive datasets, enabling them to uncover intricate patterns that facilitate the rapid discovery of novel cancer biomarkers. This technological advancement not only accelerates innovation but also enhances diagnostic accuracy, which is crucial for personalized medicine. As stakeholders increasingly recognize the potential of AI-driven insights, investment in these advanced technologies is expected to rise, positioning AI as a pivotal component in the advancement of cancer biomarker research and clinical applications.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Analysis

Global Cancer Biomarkers Market Size by Profiling Technology & CAGR (2025-2032)

Market Overview
Omics Technology
- Proteomics
- Immunoassays
- Mass Spectrometry
- 2D gel Electrophoresis
- Protein Microarrays
- Others
- Genomics
- Next Generation Sequencing
- Polymerase Chain Reaction
- In Situ Hybridization
- Others
Imaging Technologies
- Ultrasound Imaging
- Computed Tomography
- Magnetic Resonance Imaging
- Positron Emission Tomography
- Mammography

Global Cancer Biomarkers Market Size by Cancer Type & CAGR (2025-2032)

Market Overview
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma
Leukemia
Thyroid Cancer
Bladder Cancer
Non-Hodgkins Lymphoma
Kidney Cancer
Others

Global Cancer Biomarkers Market Size by Product & CAGR (2025-2032)

Market Overview
Instruments
- Imaging Instruments
- Pathology Based Instruments
- Biopsy Instruments
Consumables
- Antibodies
- Kits and Reagents
- Probes
Bioinformatics Software

Global Cancer Biomarkers Market Size by Application & CAGR (2025-2032)

Market Overview
Diagnostics
Research and Development
Prognostics
Risk Assessment
Other Applications

Global Cancer Biomarkers Market Size by End User & CAGR (2025-2032)

Market Overview
Diagnostic Laboratories
Biopharmaceutical Companies and Cros
Research and Academic Institutes
Others

Global Cancer Biomarkers Market Size & CAGR (2025-2032)

North America (Profiling Technology, Cancer Type, Product, Application, End User)
- US
- Canada
Europe (Profiling Technology, Cancer Type, Product, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Profiling Technology, Cancer Type, Product, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Profiling Technology, Cancer Type, Product, Application, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Profiling Technology, Cancer Type, Product, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V. (Germany/Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exact Sciences Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
DiaSorin S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioMerieux SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adaptive Biotechnologies Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NeoGenomics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments